National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Pembrolizumab (Keytruda®) is indicated in combination with pemetrexed and platinum chemotherapy, for the first-line treatment of metastatic non-squamous NSCLC in adults whose tumours have no EGFR or ALK positive mutations.

NCPE Assessment Process Complete
Rapid review commissioned 14/08/2018
Rapid review completed 29/08/2018
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 14/09/2018
Pre-submission consultation with Applicant 22/10/2018
Submission received from Applicant 20/12/2018
Preliminary review sent to Applicant 14/06/2019
NCPE assessment re-commenced 10/07/2019
Factual accuracy sent to Applicant 31/07/2019
NCPE assessment re-commenced 09/08/2019
NCPE assessment completed 15/08/2019
NCPE assessment outcome The NCPE recommends that pembrolizumab (Keytruda®), prescribed in combination with platinum chemotherapy plus pemetrexed for the first line treatment of non-squamous NSCLC, be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments.*


*This recommendation should be considered while also having regard to the criteria
specified in the Health (Pricing and Supply of Medial Goods) Act 2013.